Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,479 Financial Services 1,900 Healthcare 1,116 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 337 Consumer Defensive 248 Communication Services 213 Utilities 183 Energy 165 Real Estate 80

1,116 stocks · page 8 of 19

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

Guardant Health, Inc.

Deeply overvalued

Premium +463% Return to IV: -82.2%

Market implies +19.7%/yr vs model +27.3% · below model

GH Research PLC

GILEAD SCIENCES, INC.

Model IV$157.63

Discount 5% Return to IV: +5.0%

Owner yield 4.8% 10-yr IRR 6.3% · steady

Market implies +3.1%/yr vs model +4.3% · in line

Market implies +29.2%/yr vs model +14.6% · above model

Galmed Pharmaceuticals Ltd.

Greenwich LifeSciences, Inc.

Monte Rosa Therapeutics, Inc.

Market implies +25.8%/yr vs model +15.0% · above model

GLOBUS MEDICAL INC

Deeply undervalued

Model IV$183.41

Discount 59% Return to IV: +142.1%

Owner yield 3.7% 10-yr IRR 10.8% · grower

Market implies +6.9%/yr vs model +25.0% · below model

Market implies +150.0%/yr vs model +2.0% · above model

Genenta Science S.p.A.

Gossamer Bio, Inc.

Market implies +79.5%/yr vs model +15.0% · above model

GeoVax Labs, Inc.

Deeply undervalued

Discount 94% Return to IV: +1,525.4%

Market implies -50.0%/yr vs model +50.0% · below model

Structure Therapeutics Inc.

Market implies +52.6%/yr vs model +25.7% · above model

Grace Therapeutics, Inc.

Market implies -18.8%/yr vs model +15.0% · below model

GridAI Technologies Corp.

Market implies +59.5%/yr vs model +15.0% · above model

Greenland Mines Ltd

Greenland Mines Ltd

GT Biopharma, Inc.

FRACTYL HEALTH, INC.

Market implies +98.7%/yr vs model +15.0% · above model

GYRE THERAPEUTICS, INC.

Discount 29% Return to IV: +41.8%

Market implies -6.5%/yr vs model +49.9% · below model

HAEMONETICS CORP

Deeply undervalued

Model IV$171.50

Discount 40% Return to IV: +67.0%

Owner yield 3.8% 10-yr IRR 7.5% · moderate

Market implies +1.8%/yr vs model +10.4% · below model

HALOZYME THERAPEUTICS, INC.

Deeply undervalued

Model IV$316.93

Discount 66% Return to IV: +193.6%

Owner yield 3.7% 10-yr IRR 10.7% · grower

Market implies +4.8%/yr vs model +25.0% · below model

HARVARD BIOSCIENCE INC

Market implies +37.0%/yr vs model +2.0% · above model

HCA Healthcare, Inc.

Deeply undervalued

Model IV$1,284.29

Discount 67% Return to IV: +200.3%

Owner yield 5.9% 10-yr IRR 14.7% · moderate

Market implies -4.4%/yr vs model +11.6% · below model

HUTCHMED (China) Ltd

Market implies +23.2%/yr vs model +11.4% · above model

HEALTHCARE SERVICES GROUP INC

Discount 17% Return to IV: +20.0%

Owner yield 4.2% 10-yr IRR 5.5% · steady

Market implies +1.3%/yr vs model +5.6% · below model

HCW Biologics Inc.

Market implies +29.2%/yr vs model +15.0% · above model

Hims & Hers Health, Inc.

Deeply undervalued

Discount 30% Return to IV: +42.7%

Market implies +0.6%/yr vs model +50.0% · below model

Vyome Holdings, Inc

Market implies +63.7%/yr vs model +2.0% · above model

Rocket One Inc.

Werewolf Therapeutics, Inc.

Harmony Biosciences Holdings, Inc.

Deeply undervalued

Model IV$319.11

Discount 87% Return to IV: +668.6%

Owner yield 10.8% 10-yr IRR 27.8% · grower

Market implies -7.8%/yr vs model +23.9% · below model

Deeply overvalued

Premium +50% Return to IV: -33.5%

Market implies +24.1%/yr vs model +25.0% · in line

HERON THERAPEUTICS, INC. /DE/

Deeply overvalued

Discount 48% Return to IV: +91.3%

Market implies -10.9%/yr vs model +15.7% · below model

HeartSciences Inc.

Market implies +93.9%/yr vs model +2.0% · above model

Heartflow, Inc.

Deeply overvalued

Premium +311% Return to IV: -75.7%

Market implies +24.0%/yr vs model +42.1% · below model

Market implies +69.5%/yr vs model +15.0% · above model

TuHURA Biosciences, Inc./NV

HURCO COMPANIES INC

Deeply undervalued

Discount 29% Return to IV: +41.1%

Market implies -4.6%/yr vs model +2.6% · below model

MindWalk Holdings Corp.

HYPERION DEFI, INC.

Market implies +92.8%/yr vs model +2.0% · above model

Hyperfine, Inc.

Deeply overvalued

Premium +93% Return to IV: -48.2%

Market implies +14.5%/yr vs model +50.0% · below model

INTEGRA LIFESCIENCES HOLDINGS CORP

Premium +18% Return to IV: -15.0%

Market implies +6.2%/yr vs model +2.0% · above model

Market implies +55.1%/yr vs model +2.0% · above model

IMPACT BIOMEDICAL INC.

Market implies +85.3%/yr vs model +2.0% · above model

ImmunityBio, Inc.

Market implies +44.8%/yr vs model +50.0% · below model

IMMUCELL CORP /DE/

Deeply overvalued

Premium +245% Return to IV: -71.0%

Market implies +21.4%/yr vs model +9.6% · above model

IceCure Medical Ltd.

Market implies +92.2%/yr vs model +2.0% · above model

SeaStar Medical Holding Corp

Market implies +13.7%/yr vs model +15.0% · in line

SeaStar Medical Holding Corp

Market implies -50.0%/yr vs model +15.0% · below model

ICU MEDICAL INC/DE

Deeply overvalued

Premium +206% Return to IV: -67.3%

Owner yield 2.6% 10-yr IRR 4.5% · grower

Market implies +25.4%/yr vs model +12.9% · above model

IDEXX LABORATORIES INC /DE

Deeply overvalued

Model IV$231.99

Premium +121% Return to IV: -54.7%

Owner yield 2.1% 10-yr IRR 0.2% · moderate

Market implies +18.9%/yr vs model +9.9% · above model

IDEAYA Biosciences, Inc.

Deeply overvalued

Premium +117% Return to IV: -53.9%

Market implies +10.3%/yr vs model +50.0% · below model